Antisoma To Cut Costs After Another Phase III Failure Of A Lead Compound
This article was originally published in The Pink Sheet Daily
Executive Summary
Antisoma could cut jobs in the U.S. and the U.K. following the failure of its potential secondary acute myeloid leukemia therapy in a Phase III clinical trial.
You may also be interested in...
U.K. Biotech Renovo's Future On The Line As Phase III Lead Crashes
The Phase III failure of Renovo's scar reduction treatment threatens the company's future and is the latest in a string of bad news for U.K. biotech.
U.K. Biotech Renovo's Future On The Line As Phase III Lead Crashes
The Phase III failure of Renovo's scar reduction treatment threatens the company's future and is the latest in a string of bad news for U.K. biotech.
Novartis And Antisoma's ASA404 Stumbles Badly In A Phase III Lung Cancer Trial
Prospects for what was thought to be a promising first-in-class lung cancer treatment dim after a Phase III trial is halted early due to futility of improving survival.